Effectiveness of empagliflozin added to automated insulin delivery (AID) systems in adults with type 1 diabetes with sub-optimal glycemic outcomes
I am coordinating a multi-center, placebo-controlled study, testing the effectiveness of empagliflozin use in conjunction with automated insulin delivery (AID) to improve glucose control in individuals with type 1 diabetes. The aim is to determine whether a low dose of empagliflozin daily would improve glycemic outcomes over a 26-week period.
To find out more about this study, please contact Jessica Troughton at jessica.troughton [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT06021145
Semaglutide and Empagliflozin Added to Automated Insulin Delivery in Adults with Type 1 Diabetes (SEMPA)
I am coordinating a randomized, double-blind, placebo-controlled, crossover trial at the MUHC, testing the effectiveness of adding both semaglutide and empagliflozin in conjunction with automated insulin delivery systems for improving glucose control. This study will compare time-in-range results across four treatment arms: semaglutide + empagliflozin, semaglutide + placebo, empagliflozin + placebo, and placebo + placebo. Each participant will complete all four treatment arms, allowing for direct comparison within individuals.
To find out more about this study, please contact Natasha Alder at natasha.alder [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT06894784
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide (SEMA)
I am currently running a phase 2/3 clinical trial testing semaglutide’s effect on carbohydrate counting in patients with type 1 diabetes using an automated insulin delivery system. Semaglutide (brand name Ozempic) is a GLP-1 receptor agonist currently approved for use in those with type 2 diabetes for better glucose control. One challenge that patients with type 1 diabetes using automated insulin delivery systems experience is the hassle of counting their carbohydrates at every meal of the day. Researchers are actively trying to find a way to reduce or eliminate the reliance of the pump systems on carbohydrate input without diminishing its effectiveness. This study aims to assess if the addition of semaglutide alongside automated insulin delivery systems can allow participants to use simple meal announcement (input same amount of carbohydrates at each meal) or fully closed loop mode (no carbohydrate input) without degrading glucose control.
To find out more about this study, please contact Carolyn Wright at carolyn.wright [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT06387199
Continuous Ketone Monitoring with Empagliflozin in Adults with Type 1 Diabetes (EmpaCKM)
I am coordinating a research study at Hygea Medical Clinic investigating ketone dynamics in adults with type 1 diabetes using a novel technology called continuous ketone monitoring (CKM). Empagliflozin, an SGLT2 inhibitor currently approved for type 2 diabetes, has been shown to improve glycemic and cardiovascular outcomes and may also benefit people with type 1 diabetes by reducing risks of chronic kidney disease and mortality.
This study explores how ketone levels fluctuate throughout the day in participants taking empagliflozin (2.5 mg and 10 mg), including during exercise and periods of low-carbohydrate intake. Participants will wear a CKM device continuously throughout the 16-week study while maintaining their usual insulin therapy.
To find out more about this study, please contact Catalina Magana at catalina.magana [at] affiliate.mcgill.ca
ClinicalTrials.gov Identifier: NCT06753994